Biotech part­ner drops Glax­o­SmithK­line’s ad­ju­vant as it moves Covid-19 vac­cine in­to PhII/III, cit­ing ‘man­u­fac­tur­ing con­sid­er­a­tions’

When Glax­o­SmithK­line re­vealed that its Sanofi-part­nered re­com­bi­nant pro­tein-based Covid-19 vac­cine pro­gram was run­ning in­to a ma­jor de­lay, the phar­ma gi­ant tucked in a para­graph …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER